Nevertheless, while waiting for a longer follow-up and the secondary OS endpoint results, the availability of a drug able to delay disease recurrence, prevent CNS metastases (a well-known critical site of relapse also after adjuvant first-generation TKIs [28]), while maintaining the patient’s quality of life, represents an important step forward in the adjuvant approach to EGFR mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.